Floatz logo

FLUDROCORTISONE

Castration-Resistant Prostate Carcinoma

Merck Sharp & Dohme LLCSmall moleculePhase 3Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
73/ 100

Competitive context

214 Active assets in the Castration-Resistant Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
Darolutamide
Bayer
Phase 4BBB
Enzalutamide
Prostate Cancer Clinical Trials Consortium
Phase 4BBB
Prednisolone
Ding-Wei Ye
Phase 4BBB
RADIUM RA-223
University of California, San Francisco
Phase 4BB
Cabozantinib
Rana McKay, MD
Phase 3BB

View all 50 →

Same molecule, other indications

FLUDROCORTISONE is also rated in:

congenital adrenal hyperplasiaActive
BB
Indicative · Phase 3
69 / 100
View asset →
Parkinson diseaseDormant
BB
Indicative · Phase 2
64 / 100
View asset →
prostate neoplasmActive
B
Indicative · Phase 3
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →